Ligand Pharmaceuticals Inc navigates the turbulent waters of the biotech sector, balancing innovative drug development with financial challenges and market volatility.

Ligand Pharmaceuticals Inc. has achieved significant milestones, including a $5 million milestone payment and a $9 million funding round, as it continues to innovate in the biotechnology sector and expand its reach into geospatial data analysis.

Ligand Pharmaceuticals Inc. is experiencing positive momentum as the NASDAQ Composite gains, with the company’s stock price increasing 6.64% amidst a broader market uptick.

Ligand Pharmaceuticals, a biotech company specializing in hormone-activated receptor-targeting drugs, has a market capitalization of $2.21 billion and a stock price of $114.98 as of June 22, 2025.